{"id":9355,"date":"2022-02-03T13:55:35","date_gmt":"2022-02-03T13:55:35","guid":{"rendered":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/"},"modified":"2022-02-03T13:55:35","modified_gmt":"2022-02-03T13:55:35","slug":"biogens-2022-outlook-leaves-investors-wanting-shares-slip","status":"publish","type":"post","link":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/","title":{"rendered":"Biogen&#8217;s 2022 outlook leaves investors wanting, shares slip"},"content":{"rendered":"<p> <a href=\"https:\/\/go.fiverr.com\/visit\/?bta=1052423&nci=17043\" Target=\"_Top\"><img loading=\"lazy\" decoding=\"async\" border=\"0\" src=\"https:\/\/mailinvest.blog\/wp-content\/themes\/breek\/assets\/images\/transparent.gif\" data-lazy=\"true\" data-src=\"https:\/\/fiverr.ck-cdn.com\/tn\/serve\/?cid=40081059\"  width=\"601\" height=\"201\"><\/a>\n<br \/><img decoding=\"async\" src=\"https:\/\/mailinvest.blog\/wp-content\/themes\/breek\/assets\/images\/transparent.gif\" data-lazy=\"true\" data-src=\"https:\/\/s.abcnews.com\/images\/Technology\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg\" \/><\/p>\n<div id=\"\">\n<div class=\"Article__Headline\">\n<p class=\"Article__Headline__Desc\">Biogen expects \u201cminimal\u201d revenue this year from its Alzheimer\u2019s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from \u00a0doctors and patient advocates<\/p>\n<\/div>\n<div class=\"Article__Header__Meta\">\n<section class=\"Byline flex items-center\">\n<div class=\"Byline__Content\">\n<p><span class=\"Byline__ByCopy\" aria-hidden=\"true\">By<\/span><span aria-hidden=\"true\" class=\"Byline__AuthorRow\"><span class=\"Byline__AuthorContainer\" to=\"\"><span class=\"Byline__Author \"> TOM MURPHY AP Health Writer<\/span><\/span><\/span><\/p>\n<div class=\"Byline__TimestampWrapper\">\n<p>February 3, 2022, 1:24 PM<\/p>\n<p><span class=\"Byline__Bullet\" aria-hidden=\"true\">\u2022 <\/span>2 min read<\/p>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"Share flex flex-no-wrap Article__Header__Share\"><button aria-label=\"Share to Facebook\" class=\"Button Button--default Button--icon-noLabel Share__Item Share__Item--facebook\" tabindex=\"0\"><svg focusable=\"false\" aria-hidden=\"true\" class=\"Share__Icon icon__svg\" viewbox=\"0 0 24 24\"><use xlink:href=\"#icon__social__facebook\"\/><\/svg><span class=\"Share__Text\">Share to Facebook<\/span><\/button><button aria-label=\"Share to Twitter\" class=\"Button Button--default Button--icon-noLabel Share__Item Share__Item--twitter\" tabindex=\"0\"><svg focusable=\"false\" aria-hidden=\"true\" class=\"Share__Icon icon__svg\" viewbox=\"0 0 24 24\"><use xlink:href=\"#icon__social__twitter\"\/><\/svg><span class=\"Share__Text\">Share to Twitter<\/span><\/button><button aria-label=\"Email this article\" class=\"Button Button--default Button--icon-noLabel Share__Item Share__Item--email\" tabindex=\"0\"><svg focusable=\"false\" aria-hidden=\"true\" class=\"Share__Icon icon__svg\" viewbox=\"0 0 24 24\"><use xlink:href=\"#icon__email\"\/><\/svg><span class=\"Share__Text\">Email this article<\/span><\/button><\/section>\n<\/div>\n<\/div>\n<div id=\"\">\n<p>Biogen expects \u201cminimal\u201d revenue this year from its Alzheimer\u2019s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates.<\/p>\n<p>The drugmaker on Thursday released a forecast for 2022 that caught investors off guard, sending shares down more than 3% before the opening bell.<\/p>\n<p>Biogen&#8217;s Alzheimer\u2019s treatment brought in only $3 million last year following its debut, but the company, based in Cambridge, Massachusetts, also reported eroding sales from other key products.<\/p>\n<p>Aduhelm entered the U.S. market after federal regulators approved it last June, but it received pushback over its initial price of more than $50,000 annually.<\/p>\n<p>Aduhelm, the first new Alzheimer\u2019s treatment in years, clears brain plaque thought to play a role in the disease\u2019s development. Regulators approved it based on study results showing the drug seemed likely to benefit patients. But they\u2019ve asked for more research.<\/p>\n<p>Several prominent medical centers around the country declined to offer it, and Biogen was forced to slash the price late last year.<\/p>\n<p>Then the federal government proposed restrictions last month for a key population, Medicare patients.<\/p>\n<p>The Centers for Medicare and Medicaid Services said in a preliminary coverage decision that patients taking Aduhelm will have to participate in another clinical trial that evaluates the drug\u2019s effectiveness in order for Medicare to cover the cost.<\/p>\n<p>The government will make a final overage decision this spring.<\/p>\n<p>Biogen CEO Michel Vountasos has said that decision, if finalized, \u201cwould deny nearly all Medicare beneficiaries\u201d access to the treatment.<\/p>\n<p>For 2022, Biogen expects adjusted per-share earnings of between $14.25 and $16 on revenue ranging from $9.7 billion to $10 billion.<\/p>\n<p>For 2022, analysts expect, on average, earnings of $18.76 per share on $10.32 billion in revenue, according to FactSet.<\/p>\n<p>The company also is factoring in a continued decline in sales for the the multiple sclerosis treatment Tecfidera in the U.S. due to cheaper, generic competition.<\/p>\n<p>Shares of Biogen Inc. fell $6.97 to $217.99.<\/p>\n<\/div>\n<iframe data-lazy=\"true\" data-src=\"https:\/\/www.fiverr.com\/gig_widgets?id=U2FsdGVkX18x7XQvttUTrv1oEqmGNGTgvvCUiUoJ\/AP4z\/UyMz8lXGOLpu15jIMxBbTR0gmD5uBoFvhC4KWeALQRp3h\/X\/AwcVD0K8Wj9H\/ZzYKzcCNHosB9oS4SCJJFWiN85P9ICAc4OgCoE\/wHKIY7CDkf2\/DQ1vqGvk4smVe5cRDEmrLPCWi4FC8p40VUhSmWQ5udCm0zoJtorgWv3vbDQw0kKYkwn39ozAnQXDe+YvWMxkLFWA+O3TFwkJvdkIK+\/AUSnRssPKt5WHY0FhNOxnSPcLslEL4G4\/RfP95ve99U+kRnDy3X+KtzdQLY+u935ghON\/o3UE4IMv9oN6JX9RnxzL\/LRcOgnHigxStSGPKsZYtnz8RWNVT\/rOLAibqiWJadC5MYHRbekF3eg6FOGrQGkXYbsn0+a5aovnlLCbLwIqY9fcS17UX8J235iQ6cdmHNbrPeS84CMm34RA==&affiliate_id=1052423&strip_google_tagmanager=true\" loading=\"lazy\" data-with-title=\"true\" class=\"fiverr_nga_frame\" frameborder=\"0\" height=\"350\" width=\"100%\" referrerpolicy=\"no-referrer-when-downgrade\" data-mode=\"random_gigs\" onload=\" var frame = this; var script = document.createElement('script'); script.addEventListener('load', function() { window.FW_SDK.register(frame); }); script.setAttribute('src', 'https:\/\/www.fiverr.com\/gig_widgets\/sdk'); document.body.appendChild(script); \" ><\/iframe>\n<br \/><a href=\"https:\/\/abcnews.go.com\/Technology\/wireStory\/biogens-2022-outlook-leaves-investors-wanting-shares-slip-82646416\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen expects \u201cminimal\u201d revenue this year from its Alzheimer\u2019s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":9356,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-9355","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech-universe"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biogen&#039;s 2022 outlook leaves investors wanting, shares slip - mailinvest.blog<\/title>\n<meta name=\"description\" content=\"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis.mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what&#039;s new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen&#039;s 2022 outlook leaves investors wanting, shares slip - mailinvest.blog\" \/>\n<meta property=\"og:description\" content=\"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis.mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what&#039;s new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/\" \/>\n<meta property=\"og:site_name\" content=\"mailinvest.blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/freelanceracademic\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-03T13:55:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/02\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"992\" \/>\n\t<meta property=\"og:image:height\" content=\"558\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin@mailinvest.blog\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin@mailinvest.blog\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/\"},\"author\":{\"name\":\"admin@mailinvest.blog\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#\\\/schema\\\/person\\\/012701c4c204d4e4ebd34f926cfd31a4\"},\"headline\":\"Biogen&#8217;s 2022 outlook leaves investors wanting, shares slip\",\"datePublished\":\"2022-02-03T13:55:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mailinvest.blog\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg\",\"articleSection\":[\"Tech Universe\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/\",\"url\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/\",\"name\":\"Biogen's 2022 outlook leaves investors wanting, shares slip - mailinvest.blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mailinvest.blog\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg\",\"datePublished\":\"2022-02-03T13:55:35+00:00\",\"description\":\"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis.mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what's new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mailinvest.blog\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg\",\"contentUrl\":\"https:\\\/\\\/mailinvest.blog\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg\",\"width\":992,\"height\":558},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/2022\\\/02\\\/03\\\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mailinvest.blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen&#8217;s 2022 outlook leaves investors wanting, shares slip\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#website\",\"url\":\"https:\\\/\\\/mailinvest.blog\\\/\",\"name\":\"mailinvest.blog\",\"description\":\"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis. mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what&#039;s new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.\",\"publisher\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mailinvest.blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#organization\",\"name\":\"mailinvest\",\"url\":\"https:\\\/\\\/mailinvest.blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mailinvest.blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/default.png\",\"contentUrl\":\"https:\\\/\\\/mailinvest.blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/default.png\",\"width\":1000,\"height\":1000,\"caption\":\"mailinvest\"},\"image\":{\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/freelanceracademic\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mailinvest.blog\\\/#\\\/schema\\\/person\\\/012701c4c204d4e4ebd34f926cfd31a4\",\"name\":\"admin@mailinvest.blog\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/98ed217bd0f3d6a6dcae2d9b0c76e305b049a07275e315e1407e19ec8b08e139?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/98ed217bd0f3d6a6dcae2d9b0c76e305b049a07275e315e1407e19ec8b08e139?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/98ed217bd0f3d6a6dcae2d9b0c76e305b049a07275e315e1407e19ec8b08e139?s=96&d=mm&r=g\",\"caption\":\"admin@mailinvest.blog\"},\"sameAs\":[\"https:\\\/\\\/mailinvest.blog\",\"admin@mailinvest.blog\"],\"url\":\"https:\\\/\\\/mailinvest.blog\\\/index.php\\\/author\\\/adminmailinvest-blog\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogen's 2022 outlook leaves investors wanting, shares slip - mailinvest.blog","description":"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis.mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what's new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/","og_locale":"en_US","og_type":"article","og_title":"Biogen's 2022 outlook leaves investors wanting, shares slip - mailinvest.blog","og_description":"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis.mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what's new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.","og_url":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/","og_site_name":"mailinvest.blog","article_publisher":"https:\/\/www.facebook.com\/freelanceracademic\/","article_published_time":"2022-02-03T13:55:35+00:00","og_image":[{"width":992,"height":558,"url":"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/02\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg","type":"image\/jpeg"}],"author":"admin@mailinvest.blog","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin@mailinvest.blog","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#article","isPartOf":{"@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/"},"author":{"name":"admin@mailinvest.blog","@id":"https:\/\/mailinvest.blog\/#\/schema\/person\/012701c4c204d4e4ebd34f926cfd31a4"},"headline":"Biogen&#8217;s 2022 outlook leaves investors wanting, shares slip","datePublished":"2022-02-03T13:55:35+00:00","mainEntityOfPage":{"@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/mailinvest.blog\/#organization"},"image":{"@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#primaryimage"},"thumbnailUrl":"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/02\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg","articleSection":["Tech Universe"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/","url":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/","name":"Biogen's 2022 outlook leaves investors wanting, shares slip - mailinvest.blog","isPartOf":{"@id":"https:\/\/mailinvest.blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#primaryimage"},"image":{"@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#primaryimage"},"thumbnailUrl":"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/02\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg","datePublished":"2022-02-03T13:55:35+00:00","description":"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis.mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what's new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.","breadcrumb":{"@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#primaryimage","url":"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/02\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg","contentUrl":"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/02\/WireAP_98f28ff978a34ce08d049eabb8a35517_16x9_992.jpg","width":992,"height":558},{"@type":"BreadcrumbList","@id":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/03\/biogens-2022-outlook-leaves-investors-wanting-shares-slip\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mailinvest.blog\/"},{"@type":"ListItem","position":2,"name":"Biogen&#8217;s 2022 outlook leaves investors wanting, shares slip"}]},{"@type":"WebSite","@id":"https:\/\/mailinvest.blog\/#website","url":"https:\/\/mailinvest.blog\/","name":"mailinvest.blog","description":"Technology is forever changing, and there are always new pieces of technology to replace obsolete ones. Tons of people enjoy reading tech blogs on a daily basis. mailinvest.blog tracks all the latest consumer technology breakthroughs and shows you what&#039;s new, what matters and how technology can enrich your life. mailinvest.blog also provides the information, tools, and advice that helps when deciding what to buy.","publisher":{"@id":"https:\/\/mailinvest.blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mailinvest.blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mailinvest.blog\/#organization","name":"mailinvest","url":"https:\/\/mailinvest.blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mailinvest.blog\/#\/schema\/logo\/image\/","url":"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/01\/default.png","contentUrl":"https:\/\/mailinvest.blog\/wp-content\/uploads\/2022\/01\/default.png","width":1000,"height":1000,"caption":"mailinvest"},"image":{"@id":"https:\/\/mailinvest.blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/freelanceracademic\/"]},{"@type":"Person","@id":"https:\/\/mailinvest.blog\/#\/schema\/person\/012701c4c204d4e4ebd34f926cfd31a4","name":"admin@mailinvest.blog","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/98ed217bd0f3d6a6dcae2d9b0c76e305b049a07275e315e1407e19ec8b08e139?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/98ed217bd0f3d6a6dcae2d9b0c76e305b049a07275e315e1407e19ec8b08e139?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/98ed217bd0f3d6a6dcae2d9b0c76e305b049a07275e315e1407e19ec8b08e139?s=96&d=mm&r=g","caption":"admin@mailinvest.blog"},"sameAs":["https:\/\/mailinvest.blog","admin@mailinvest.blog"],"url":"https:\/\/mailinvest.blog\/index.php\/author\/adminmailinvest-blog\/"}]}},"_links":{"self":[{"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/posts\/9355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/comments?post=9355"}],"version-history":[{"count":0,"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/posts\/9355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/media\/9356"}],"wp:attachment":[{"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/media?parent=9355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/categories?post=9355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailinvest.blog\/index.php\/wp-json\/wp\/v2\/tags?post=9355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}